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ABSTRACT
Cytomegalovirus (CMV)-based vaccine vectors are promising vaccine platforms 
because they induce strong and long-lasting immune responses. Recently it has been 
shown that vaccination with a mouse CMV (MCMV) vector expressing the melanoma-
specific antigen TRP2 (MCMV-TRP2) protects mice against outgrowth of TRP2-positive 
B16 melanoma tumors, and this protection was dependent on the induction of IgG 
antibodies. Here we demonstrate that, although mice lacking all receptors for the Fc 
part of IgG (FcγRs) develop normal IgG responses after MCMV-TRP2 vaccination, the 
protection against B16 melanoma was completely abrogated, indicating that FcγRs 
are indispensable in the downstream effector pathway of the polyclonal anti-TRP2 
antibody response. By investigating compound FcγR-deficient mouse strains and by 
using immune cell type-specific cell ablation we show that the IgG antibody-mediated 
tumor protection elicited by MCMV-TRP2 mainly depends on FcγRI expression on 
macrophages, whereas FcγRIV plays only a modest role. Thus, tumor-specific antibody 
therapy might benefit from combination therapy that recruits FcγRI-expressing pro-
inflammatory macrophages to the tumor micro-environment.
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INTRODUCTION
Most vaccines against cancer exhibit less impressive 
results in comparison with the clinical results of 
immunomodulatory antibodies and adoptive T cell therapy 
(ACT) [1]. This could be attributed due to various immune 
evasion mechanisms and to the failure of inducing long-
lasting sustainable functional T and B cell responses. 
With respect to the latter, cytomegalovirus (CMV)-based 
vaccines hold great potential because of the ability of 
CMV to elicit large adaptive immune responses that are 
maintained without contracting [2]. This phenomenon, 
termed memory inflation, is observed for the increase in 
effector-memory T cell populations [3] as well as for IgG 
antibodies [4]. Other properties such as the ability of CMV 
to re-infect despite pre-existing immunity [5, 6] and the 
adaptability of CMV for genetic engineering [7], thereby 
even allowing large insertions of foreign DNA without 
losing viral replication potential, also contribute to the 
value of CMV as a vaccine vector.
The efficacy of CMV as a cancer vaccine 
vector has been demonstrated in several preclinical 
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models by using MCMV vectors containing prostate 
specific antigen (PSA), melanoma antigens (gp100, 
tyrosinase-related protein-2 (TRP-2)) or model antigens 
(ovalbumin) [8–11]. While the efficacy of most of 
these MCMV vaccine vectors was centred on the 
induction of large effector-memory T cell responses, the 
effectiveness of the MCMV-TRP2 vector was antibody 
dependent [10], but the mechanisms of actions of the 
TRP2 antibody-mediated tumor protection remain to be 
determined.
The B16 transplantable melanoma model is 
widely used to study underlying mechanisms of tumor-
specific antibody-based therapy [12–19]. In most studies 
the IgG2c (the equivalent of IgG2a in C57BL/6 mice) 
monoclonal antibody TA99 [12–16, 19] or other IgG 
subclasses engineered from it [17, 18] specific for the 
B16-F10 antigen TRP1 (gp75) were used. In addition, 
active immunisation with gp75 protein was applied [15]. 
In contrast to anti-HER2/Neu antibody in breast cancer, 
TA99 does not interfere with cell signalling when bound 
to its tumor target and has no direct effect on growth or 
survival of tumor cells. Therefore, the therapeutic efficacy 
of TA99 depends on its ability to recruit effector cells 
of the immune system, which can kill the tumor cells 
by different mechanisms including antibody dependent 
cell cytotoxicity (ADCC), antibody dependent cell 
phagocytosis (ADCP), trogocytosis [20], complement 
dependent cell-mediated phagocytosis (CDCP), and cell-
mediated cytotoxicity (CDCC) [21]. 
Four different FcγRs have been identified in the 
mouse. The IgG binding α-chains of the activating 
FcγRI, FcγRIII and FcγRIV are associated with the FcR 
γ chain, a signal transduction subunit that is also required 
for cell surface expression. The activating FcγR are 
counterbalanced by the inhibiting receptor FcγRIIb. The 
four FcγRs are expressed in different combinations on a 
variety of immune cells, mainly myeloid effector cells 
[22, 23]. Different laboratories reported contradictory 
results regarding the involvement of the individual 
activating FcγRs using one of the three B16-F10 tumor 
model variants and different panels of FcγR deficient mice 
and FcγR blocking antibodies [13, 14, 17–19]. 
Here we aim to decipher the underlying mechanisms 
of the anti-tumor effects of TRP2 polyclonal antibodies 
elicited by MCMV-TRP2 vaccination through 
investigating the individual role of the activating 
FcγRI, FcγRIII and FcγRIV and the different FcγR-
expressing immune effector cells. We demonstrate 
that after immunization with the MCMV-TRP2 vector, 
the protection against tumor outgrowth mediated by 
the elicited polyclonal TRP2 antibodies is completely 
abrogated in FcγRI-deficient mice and partially diminished 
in FcγRIV−/− mice. Cell subset depletion revealed that 
macrophages were the main innate effector immune cells 
involved.
RESULTS
Germinal center reactions and antibody 
responses during CMV infection are not FcγR 
dependent
To investigate the particular role of FcγRs in the 
antibody-mediated protection induced by MCMV-TRP2 
vectors [10], we initially aimed to investigate whether 
FcγRs impact B cell responses including the development 
of germinal center (GC) B cells and plasma cells, T 
follicular helper (TFH) cell responses, and antibody 
responses upon CMV infection.
Wild-type (WT) C57BL/6 mice and mice lacking all 
four FcγRs were infected with MCMV-Smith and analysed 
at day 14 post-infection. The GC B cell responses, and 
plasma cells were slightly increased in FcγRI/II/III/IV−/− 
mice (Figure 1A and 1B) compared to WT mice, while 
the GC TFH cell responses were comparable (Figure 
1C and 1D). The IgG antibody responses specific to 
MCMV at day 14 post-infection with MCMV-Smith 
were comparable between WT and FcγRI/II/III/IV−/− mice 
(Figure 2A). Consistent with natural infection, the IgG 
antibody responses (total IgG, IgG1, IgG2c) to MCMV 
after vaccination with MCMV-TRP2 were also similar 
in WT and FcγRI/II/III/IV−/− mice (Figure 2B–2D). 
Thus, FcγRs have a minor impact on GC reactions and 
antibody formation, indicating that potential effects of 
FcγR-deficiency cannot be attributed to insufficiencies in 
antibody responses. 
FcγRI is predominantly required for the 
antibody-mediated tumor protection induced by 
MCMV-TRP2 vaccination 
Next, we aimed to analyse whether FcγRs play a 
role in the IgG-mediated effector mechanisms that are 
operational during tumor protection upon vaccination with 
MCMV-TRP2. To determine whether the MCMV-TRP2-
induced anti-tumor immunity is FcγR dependent, WT 
mice and mice deficient in all four FcγRs were vaccinated 
with MCMV-TRP2, and two weeks later challenged with 
B16 tumor cells. In untreated WT and FcγRI/II/III/IV−/− 
mice the outgrowth of B16 tumor was similar. In contrast, 
MCMV-TRP2 vaccination elicited a clearly delayed onset 
of B16 tumor outgrowth in WT mice but not in FcγRI/
II/III/IV−/− mice (Figure 3). Thus, the antibody-mediated 
protection induced by MCMV-TRP2 vaccination is FcγR 
dependent.
The expression profiles vary between FcγR classes 
as well as the downstream antibody effector functions 
they facilitate. To gain insight in the contribution of 
the individual activating FcγRs, the protection against 
outgrowth of the B16 tumor after vaccination with 
MCMV-TRP2 was analysed in mice deficient for one 
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or two FcγR classes. The generation of FcγRIV−/− 
and FcγRIII/IV−/− mouse strains is described in the 
Supplementary Data. FcγRI−/−, FcγRIII−/−, FcγRIV−/− and 
FcγRIII/IV−/− mice were vaccinated with MCMV-TRP2 
or left unvaccinated, and two weeks later challenged with 
B16 tumor cells. All unvaccinated WT and FcγR−/− mice 
developed progressive tumors within 2–3 weeks after 
challenge. Whereas vaccinated WT and FcγRIII−/− mice 
showed a substantial increased survival, MCMV-TRP2 
vaccinated FcγRI−/− mice did not (Figure 4A and 4B). 
FcγRIV−/− and FcγRIII/IV−/− mice showed a delay in tumor 
outgrowth, albeit significantly less compared to MCMV-
TRP2 vaccinated WT mice (Figure 4C). Taken together 
these data suggest that FcγRI plays a dominant role in the 
Figure 1: Germinal center reactions upon CMV infection are not abrogated in mice lacking all FcγRs. (A–D) WT and 
FcγRI/II/III/IV−/− mice were infected with MCMV-Smith and at day 14 post-infection the B cell and T cell germinal center (GC) responses 
in the spleen were examined. Representative flow cytometry plots are shown. (A–B) Percentage and absolute number of plasma cells 
(CD138+IgD–) and GC B cells (GL7+) within splenic CD19+ B220+ B cells in WT and FcγRI/II/III/IV−/− mice. (C–D) Percentage and total 
cell numbers of (C) TFH (CXCR5
+PD1+) cells and (D) GC TFH (CXCR5
+GL7+) cells within CD4+CD3+ T cells are shown. Results from one 
representative experiment out of three performed are shown (*p < 0.05, n = 5).
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antibody-mediated tumor protection induced by MCMV-
TRP2 vaccination whereas FcγRIV has moderate impact.
Tumor protection by MCMV-TRP2 vaccination 
predominantly requires macrophages
FcγRs are variably expressed by different cell types 
including phagocytic myeloid cells, neutrophils and NK 
cells [22, 23]. To determine which FcγR-expressing 
effector cell types are involved in the antibody mediated 
tumor protection induced by MCMV-TRP2 vaccination, 
the outgrowth of B16 cells was monitored after s.c. 
transplantation, followed two days later by depletion of the 
following cell types: macrophages (depleted by clodronate 
liposomes), neutrophils (depleted by anti-Ly6G antibody) 
and NK cells (depleted by anti-NK1.1 antibody). After 
the depletion of macrophages, the protection against B16 
tumor challenge upon MCMV-TRP2 vaccination was 
Figure 2: FcγR deficiency does not alter the anti-MCMV antibody response after MCMV-TRP2 vaccination. (A) 
Levels of MCMV-specific total IgG in serum of WT and FcγRI/II/III/IV−/− mice at day 14 post-infection with MCMV-Smith. Measurement 
at OD450 of 1:400 diluted serum. (B) Levels of MCMV-specific total IgG in serum of WT and FcγRI/II/III/IV−/− mice at day 14 post 
vaccination with MCMV-TRP2. Measurement at OD450 of 1:100 diluted serum. (C) Levels of MCMV-specific IgG1 in serum of WT 
and FcγRI/II/III/IV−/− mice at day 14 post vaccination with MCMV-TRP2. Measurement at OD450 of 1:100 diluted serum. (D) Levels of 
MCMV-specific IgG2c in serum of WT and FcγRI/II/III/IV−/− mice at day 14 post vaccination with MCMV-TRP2. Measurement at OD450 
of 1:100 diluted serum. 
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abrogated while depletion of NK cells had a slight effect. 
In addition, depletion of neutrophils did not alter tumor 
protection (Figure 5A and 5B). 
The dominant importance of macrophages is in line 
with the expression of the FcγRs on these cells. Notably, 
FcγRI is highly expressed on inflammatory macrophages 
(Ly6C+ F4/80+) residing in the tumor and spleen (Figure 
5C). Neutrophils express FcγRIII and FcγRIV, while 
NK cells only express low levels of FcγRIII. Thus, 
macrophages expressing high levels of FcγRI are the 
Figure 3: Protection against B16 tumor outgrowth by MCMV-TRP2 vaccination is FcγR dependent. WT and FcγRI/
II/III/IV−/− mice were vaccinated with MCMV-TRP2 or left unvaccinated, and at day 14 post-vaccination challenged with B16 tumor 
cells. (A) Tumor growth curves of B16 tumor challenged WT and FcγRI/II/III/IV−/− mice following MCMV-TRP2 vaccination. Numbers 
at the bottom right of each panel represent the number of mice from total that succumbed to the tumor challenge. (B) Survival of B16 
tumor-bearing WT and FcγRI/II/III/IV−/− mice following vaccination with MCMV-TRP2. Results are shown from two pooled experiments 
(*p < 0.05, **p < 0.01, n = 10).
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dominant cell type involved in the tumor protecting effects 
mediated by polyclonal antibodies elicited via MCMV-
TRP2 vaccination.
Macrophages mediate antibody-dependent 
killing of tumor cells 
To gain insight into the mechanisms of macrophage-
dependent killing of the B16 tumor cells, we first 
performed cell surface stainings of B16 tumor cells with 
serum from MCMV-TRP2 vaccinated WT and FcγRI/II/
III/IV−/− mice followed by an Alexa488-conjugated anti-
mouse IgG specific antibody (Figure 6A and 6B). The cell 
surface of the B16 tumor cells were positively stained with 
serum from MCMV-TRP2 vaccinated WT mice while 
serum from unvaccinated WT mice or serum from WT 
mice that were infected with MCMV not expressing TRP2 
resulted in negative staining. Staining with serum from 
MCMV-TRP2 vaccinated FcγRI/II/III/IV−/− mice resulted 
also in a positive cell surface staining whereas serum from 
unvaccinated FcγRI/II/III/IV−/− mice did not.
To show that macrophages can kill B16F10 cells via 
serum antibodies that are able to bind to the cell surface 
of the B16F10 cells, we co-cultured these tumor cells 
with macrophages (RAW264.7, a murine macrophage cell 
line) in presence and absence of serum of vaccinated and 
non-vaccinated mice. We observed that only serum from 
MCMV-TRP2 vaccinated mice resulted in lysis of the 
tumor cells (Figure 6C). Thus, macrophages can mediate 
killing of the B16F10 cells via serum antibodies elicited 
by the MCMV-TRP2 vaccine, indicating that ADCP is the 
main effector mechanism involved. 
DISCUSSION
This study shows that a MCMV-based vaccine 
vector, expressing the full native protein of the melanoma 
specific antigen TRP2, induced a strong polyclonal 
antibody response independent of FcγRs. However, 
these tumor-specific antibodies required FcγRs for their 
protective effects against the outgrowth of the TRP2 
expressing B16 melanoma cells. In particular, FcγRI and 
to a lower extend FcγRIV expressed on macrophages was 
required for the tumor protection. 
A previous study showed that protection against 
tumor outgrowth by vaccination with MCMV-TRP2 
was not dependent on CD8 or CD4 T cells but rather on 
antibodies [10]. Other MCMV-based vaccinations in mice 
have shown to be dependent on the induction of tumor-
specific CD8 T cell responses [8, 9, 11, 24]. The most 
effective anti-tumor CD8 T cell responses were induced 
with MCMV vectors expressing altered versions or short 
Figure 4: Protection against B16 tumor outgrowth by MCMV-TRP2 vaccination is mainly FcγRI dependent. WT 
mice and mice deficient in one or more FcγRs were vaccinated with MCMV-TRP2 or left unvaccinated, and at day 14 post-vaccination 
challenged with B16 tumor cells. (A) Survival of B16 tumor challenged WT and FcγRI−/− mice. (B) Survival of B16 tumor challenged 
WT and FcγRIII−/− mice. (C) Survival of B16 tumor challenged WT, FcγRIV−/− and FcγRIII/IV−/− mice. Results shown are from two pooled 
experiments (*p < 0.05, **p < 0.01 n = 5–11).
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peptides derived from tumor antigens instead of the full 
native protein. The MCMV vector used in this study, 
MCMV-TRP2, expresses the full native TPR2 protein, 
which might explain the elicitation of antibody responses 
rather than CD8 T cell responses. 
We explored the underlying mechanisms of 
the therapeutic effect of the polyclonal IgG response 
induced by MCMV-TRP2. We found that the therapeutic 
efficacy depended mainly on FcγRI and partially on 
FcγRIV. Macrophages, expressing high levels of FcγRI 
and FcγRIV, were in particular crucial for the efficacy 
of MCMV-TRP2, indicating that FcγRI expression on 
macrophages is crucial. Most likely crosslinking of the 
high affinity FcγRI on macrophages induces ADCP of 
the B16 tumor cells located subcutaneously. Consistent 
with this are the results of experiments using intravital 
microscopy in which it was shown that ADCP by 
macrophages is prominent in the removal of circulating 
Figure 5: Protection against B16 melanoma outgrowth by MCMV-TRP2 vaccination requires macrophages. WT mice 
were vaccinated with MCMV-TRP2 or left unvaccinated, and at day 14 post-vaccination challenged with B16 tumor cells. Macrophages, 
NK cells or neutrophils were depleted right before and during tumor challenge. (A) Tumor growth curves of B16 tumor challenged WT 
mice in which the indicated cell subsets have been depleted following vaccination with MCMV-TRP2. Numbers at the bottom right of 
each panel represent the number of mice from total that survived the treatment. Results are shown from two pooled experiments. (B) 
Survival of B16 tumor-bearing WT mice in which the indicated cell subsets have been depleted following vaccination with MCMV-TRP2. 
Results are shown from two pooled experiments (*p < 0.05, **p < 0.01, n = 9–11). (C) Expression of FcγRI, FcγRII, FcγRIII and FcγRIV on 
inflammatory macrophages (F4/80+ Ly6C+), stationary macrophages (F4/80+ Ly6C−), neutrophils (Ly6G+)  and NK cells (NK1.1+) in tumor 
and spleen of unvaccinated mice at day 14 post tumor challenge.
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tumor cells through FcγRI and FcγRIV [16]. ADCP may 
thus be important for cancer vaccines inducing antibody 
responses and for antibody therapy of cancer. NK cells 
seem to play a minor role in the anti-tumor protection by 
the MCMV-TRP2 vaccine. Since NK cells only express 
FcγRIII and this FcγR is not important in the anti-tumor 
effects elicited by the MCMV-TRP2 vaccine vector it is 
expected that the minor anti-tumor effect of NK cells is 
not mediated via FcγRIII and antibodies. 
MCMV-TRP2 induced a polyclonal IgG antibody 
response of different subclasses that are known to 
mediate different downstream effector functions. Most 
tumor-specific antibodies currently used in clinics are 
monoclonal antibodies. These antibodies have mostly 
been humanized for their usage in patients. It is known 
that entirely human antibodies are longer lasting as they 
have a lower likehood to induce anti-antibody responses 
[25]. Essentially, vaccination should be able to induce 
fully human antibodies against the tumor target. Moreover, 
polyclonal antibodies inititate responses against multiple 
epitopes thereby minimizing tumor escape. Furthermore, 
it has been reported that antibodies recognizing multiple 
epitopes of epidermal growth factor receptor (EGFR) 
were able to induce complement-dependent tumor cell 
killing while a monoclonal antibody was not [26]. As such 
polyclonal antibodies against multiple epitopes could thus 
also be better at inducing complement-dependent lysis. A 
mixture of specificities in serum has been shown to induce 
increased complement activation [27]. Although, in this 
study we found a promonent role for FcγR-dependent 
mechanisms, we do not rule out that complement induced 
lysis could also play a role. 
In conclusion our study showed that MCMV-based 
vaccine vectors can induce strong IgG antibody responses 
against tumors involving FcγRI expressing macrophages. 
We anticipate that additional treatments, such as those 
counter-acting the immunosuppressive tumor micro-
environment, could act in synergy in order to improve 
the therapeutic efficacy of antibodies. Thus, CMV-based 
vectors are promising anti-cancer vaccines and may 
become a potent component of an effective combination 
therapy in cancer. 
MATERIALS AND METHODS
Mice and antibodies 
Mice were housed in the SPF animal facilities of the 
Central Animal Facility (PDC) of the Leiden University 
Medical Center (LUMC). The health status of the animals 
was monitored over time. Animals tested negative for all 
agents listed in the FELASA (Federation of European 
Laboratory Animal Science Associations) guidelines for 
SPF mouse colonies. All mouse studies were approved by 
the animal ethics committee of the LUMC. Experiments 
were performed in accordance with the Dutch Act on 
Animal Experimentation and EU Directive 2010/63/
EU (‘On the protection of animals used for scientific 
purposes’). C57BL/6J mice were purchased from Charles 
River laboratories. FcγR−/− mice were generated in the 
transgenic mouse facility of the LUMC (i.e., FcγRI−/− 
[28], FcγRI/II/III/IV−/− [29]. The generation of FcγRIV−/− 
and FcγRIII/IV−/− mouse strains is described in the 
Supplementary Data (Supplementary Figures 1 and 2). 
Figure 6: Macrophages mediate antibody-dependent killing of tumor cells. (A) Histogram showing cell surface staining of 
B16-F10 tumor cells with 1:100 diluted serum from MCMV infected mice (day 14 post infection), MCMV-TRP2 vaccinated mice (day 
14 post-vaccination), and unvaccinated mice. Tumor cells were first incubated with serum and subsequently stained with an Alexa488-
conjugated anti-mouse IgG specific antibody. (B) B16-F10 tumor-specific staining as described above with no serum and with serum from 
MCMV infected mice (day 14 post infection), unvaccinated WT and FcγRI/II/III/IV−/− mice, and MCMV-TRP2 vaccinated WT and FcγRI/
II/III/IV−/− mice (day 14 after vaccination). (C) B16-F10 tumor cells were incubated with macrophages in absence of serum or in presence 
of serum from non-vaccinated mice and MCMV-TRP2 vaccinated mice (*p < 0.05). The number of tumor cells is indicated.
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The EIIaCre deleter strain (>20 generations backcrossed 
on a C57BL/6J background), was a kind gift of Dr. Heiner 
Westphal. The Flp deleter strain C57BL/6-Tg(CAG-
flpe)36Ito/ItoRbrc (>20 generations backcrossed on a 
C57BL/6J background) was purchased from Jackson 
Laboratories (Bar Harbor, Me). Mice were routinely 
checked for their genotype by PCR analysis. 
Vaccination, tumor challenge, and cell subset 
depletion 
WT C57BL/6J, FcγRI−/−, FcγRIII−/−, FcγRIV−/− and 
FcγRIII/IV−/− mice were intraperitoneally (i.p.) inoculated 
with 2 × 106 pfu MCMV-TRP2 [10] (kindly provided by 
Ann Hill, Department of Molecular Microbiology and 
Immunology, Oregon Health and Science University, 
Portland, Oregon, USA). Mice were 14 days post 
vaccination subcutaneously (s.c.) challenged with 2 × 
105 B16-F10 melanoma cells in 100 µl PBS. Tumor 
growth was measured two or three times a week in three 
dimensions (width, length and height) using a caliper. 
Mice were euthanized when tumor size reached >2,000 
mm3 in volume or when mice lost >20% of their total body 
weight (relative to initial body mass). Mice were bled for 
serum samples at day 7, 14 and 21 days after infection. 
To examine germinal center (GC) responses, WT 
C57BL/6J and FcγRI/II/III/IV−/− mice were infected with 
5 × 104 pfu MCMV-Smith or 2 × 106 pfu MCMV-TRP2 
and at day 14 post-infection spleens were harvested and 
the plasma cells, GC B cells, T follicular helper (TFH) cells, 
GC TFH cells were analyzed by flow cytometry.
For specific cell subset depletion, vaccinated 
and unvaccinated mice were injected with either 200 μl 
clodronate liposomes intravenously (Liposoma B.V.), 100 
μg anti-NK1.1, or 100 μg anti-Ly6G (1A8) (Bioxcell) 
intraperitoneally once a week starting two days before 
tumor inoculation to deplete phagocytic macrophages, 
NK cells or neutrophils, respectively. Blood samples were 
analysed by flow cytometry to determine the efficacy of 
the cell subset depletion. 
Flow cytometry
Blood cells, tumor cells and splenocytes were 
phenotyped by flow cytometry as described [4, 30]. 
Briefly, single cell suspensions of spleens were prepared 
by mincing the spleens through 70-μm cell strainers (BD 
Biosciences). For FcγR cell surface staining of tumor-
infiltrated immune cells, tumors were isolated from 
mice that were transcardially perfused with PBS-EDTA. 
Subsequently, tumors were mechanically disrupted 
in small pieces, incubated for 15 minutes at 37° C 
in Iscove’s modified Dulbecco’s medium (IMDM)–
containing Liberase (Roche), minced through 70 μm cell 
strainers and resuspended in staining buffer (PBS + 2% 
FSC + 0.05% sodium azide) containing antibodies for 
30 minutes at 4° C. Erythrocytes were removed by 
hypotonic lysis. 
Fluorochrome-labelled antibodies specific for CD3, 
CD4, CD8, CD11b, CD95, CD138, GL7, Ly6C, Ly6G, 
F4/80, FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), 
FcγRIV (CD16.2), NK1.1 and IgD, were purchased 
from BD Biosciences, Biolegend, eBioscience and 
R&D Systems. Samples were acquired with LSRII flow 
cytometers (BD Biosciences) and data was analyzed with 
FlowJo software (TreeStar).
To stain B16-F10 tumor cells with serum, cells were 
plated in 48 well plates and incubated with serum obtained 
from MCMV-TRP2 and MCMV vaccinated mice at day 
14 post-infection. Subsequently, cells were stained with 
Alexa488-conjugated goat anti-mouse as a secondary 
antibody, and subjected to flow cytometry as described 
above.
ELISA
MCMV-specific antibodies in serum were detected 
by ELISA as described [31]. Briefly, 96-well plates (Nunc 
maxisorp) were coated overnight 4° C with NIH-3T3 
derived MCMV-Smith in bicarbonate buffer. Plates were 
then blocked at 37° C with blocking buffer (5 % milk in 
PBS) for 1 hour. Sera were diluted in 1% milk PBA and 
incubated in the blocked wells for 1 hour. HRP conjugated 
anti-IgG antibodies (Southern biotech, Birmingham, USA) 
were diluted 1:4000 in 1% milk PBS and incubated 1 hour 
at 37° C. To develop the plates 100 μl of TMB (sigma 
Aldrich) was added to each well and incubated for 15 min 
at room temperature after which 100 μl of stop solution 
(1 M H2SO4) was added. Plates were measured using a 
microplate reader. 
ADCP assay 
Macrophages (RAW264.7) were incubated with 
B16-F10 cells in a 2:1 ratio in 96 well plates. Serum from 
MCMV-TRP2 vaccinated mice, unvaccinated or no serum 
was added to the wells. 48 hours later the number of tumor 
cells were determined by flow cytometry.
Statistics
Mann–Whitney tests were used to check statistical 
significance between groups in antibody titers and number 
of positive cells. Mantel-Cox rank tests were used to check 
significance between survival of mice between groups 
from Kaplan Meier plots. 
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